Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir

Clin Infect Dis. 2021 Aug 2;73(3):e811-e814. doi: 10.1093/cid/ciab057.

Abstract

Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.

Keywords: ART; HIV; NAFLD.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Prospective Studies
  • Quinolones* / adverse effects
  • Raltegravir Potassium / adverse effects

Substances

  • Quinolones
  • Raltegravir Potassium
  • elvitegravir

Associated data

  • ClinicalTrials.gov/NCT02382822